A comprehensive view of Eisai Co. Ltd.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA grants accelerated approval to Biogen and Eisai's anti-amyloid beta protofibril antibody candidate Leqembi lecanemab to treat early Alzheimer's disease; Eisai has set wholesale acquisition cost for the drug at US$26,500 per year
Published: January 10, 2023 by Zack's Commentary
Astellas Pharma, Eisai, Daiichi Sankyo and Takeda to collaborate in development of more environmentally friendly packaging for pharmaceutical products; potential solutions could include blister packs made of biomass-based plastic
Published: December 22, 2022 by PR Newswire
Japan’s Eisai Co. reports its injectable Alzheimer’s drug lecanemab, reduced clinical decline in patients with early-stage Alzheimer’s by 27% in late-stage study; Eisai seeks accelerated approval from FDA, with Eisai and Biogen co-promoting the drug
Published: September 28, 2022 by Associated Press
Eisai opens 332,800 square-foot US headquarters in Nutley, New Jersey, with 800 person staff, bringing North American staff count up to 1,982 employees; company expects FDA decision in January on its lecanemab Alzheimer’s drug co-developed with Biogen
Published: August 23, 2022 by FiercePharma
FDA accepts Biogen’s BLA seeking accelerated approval of injectable anti-amyloid beta protofibril antibody lecanemab BAN2401 to treat early Alzheimer's disease; Biogen and Eisai collaborated to develop lecanemab
Published: July 07, 2022 by Zack's Commentary

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count